Cost Benefits and Considerable Scientific Expertise Provide China Strategic Advantage

With fast-paced advancements in genomics, combinatorial chemistry, and high-throughput screening, China has emerged as a major location to which drug discovery is being outsourced. China has the advantages of scientific expertise and comprehensive infrastructure, which are critical for drug discovery activities.

Apart from India, China is also regarded as a lucrative market able to help pharmaceutical companies to improve drug discovery at a reasonable cost. The rise of overhead costs in the United States and European countries has led companies to opt for outsourcing of drug discovery to low-cost countries, such as India and China.

New analysis from Frost & Sullivan, Drug Discovery Outsourcing Market in China, finds that the market reached $315.0 million in 2009 and is expected to grow at a compound annual growth rate (CAGR) of 23.0 percent from 2009 to 2016.

"Expired patents and the rise in diseases are expected to fuel the growth of the Chinese drug discovery market," says Frost & Sullivan Research Analyst Amritpall Singh. "China offers a large talent pool in the field of pharmaceutical research and development, including an increasing number of western-educated graduates or researchers having international working experience."

The Chinese Government has been providing strong incentives to nurture the domestic pharmaceutical and biopharmaceutical industries. The R&D sector in China has largely benefited from these initiatives, which include tax relief, direct funding opportunities, and development of numerous technology/biotechnology parks, especially in Shanghai.

Although the prospects for the market look upbeat, there are some challenges clouding its landscape. With economic reforms and the expected inflation in China, labor and raw material cost is increasing. The impact is not likely to be felt immediately. However, in the near future, cost is bound to witness a hike. Companies are expected to be scouting around for alternative locations that can offer more cost-effective options.

Apart from this, data security and intellectual property (IP) protection in China have caused some angst for large international pharmaceutical and biotechnology companies. The Government is stepping up efforts to address IP issues; however, it is likely to take a while before these problems are ironed out.

Pharmaceutical companies have displayed a preference for a single outsourcing company instead of multiple providers for a project. This helps eliminate dealings with numerous outsourcing companies and enables optimal leverage of the knowledge obtained during the early stages of R&D process within the same organization.

As the environment encourages companies to conduct vigorous R&D in this space, they must strive to move up the value chain and attain global standards at par with large western pharmaceutical companies. "Multinational companies as well as local sponsors perceive overall service quality as the uppermost priority in the selection of an outsourcing partner," says Singh. "In addition, factors such as price, ability to recruit trial participants, speed of project turnaround, as well as reputation of the drug discovery firm are also the major decisive factors."

Companies that have capitalized on the available resources for drug discovery are also keen to broaden their business horizons and build up sales in the Chinese market. Thus, new opportunities are unfolding for the development of drugs especially relevant for the Chinese market.

If you are interested in more information on Frost & Sullivan's latest research on the Drug Discovery Outsourcing Market in China, please send an e-mail to Katja Feick, Corporate Communications, at This email address is being protected from spambots. You need JavaScript enabled to view it., with your full name, company name, title, telephone number, company e-mail address, company website, city, state and country.

Drug Discovery Outsourcing Market in China is part of the Pharmaceuticals & Biotechnology Growth Partnership Services program, which also includes research in the following markets: CEO 360 Degree Perspective: Global Drug Discovery Technologies and Overview of the European Drug Discovery Market All research services included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 40 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.

Most Popular Now

Regorafenib to be tested in brain cancer patients …

Bayer announced that the regorafenib arm of the platform trial "GBM AGILE" (Glioblastoma Adaptive Global Innovative Learning Environment) opened for enrollment in the US ...

Sanofi and Google to develop new healthcare Innova…

Sanofi and Google will establish a new virtual Innovation Lab with the ambition to radically transform how future medicines and health services are delivered by tapping i...

Bristol-Myers Squibb provides update on pending me…

Bristol-Myers Squibb Company (NYSE: BMY) today provided an update on the approval process and timeline for the Company’s pending merger with Celgene Corporation (NASDAQ: ...

Japan becomes the first country to approve Roche's…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Rozlytrek® (entrectinib) for the treatment of a...

Breztri Aerosphere (PT010) approved in Japan for p…

AstraZeneca announced that Breztri Aerosphere (budesonide/glycopyrronium/ formoterol fumarate), formerly PT010, has been approved in Japan as a triple-combination therapy...

FDA approves Amgen and Allergan's KANJINTITM (tras…

Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) announced that the U.S. Food and Drug Administration (FDA) has approved KANJINTITM (trastuzumab-anns) for all approved ind...

Vitamin D may not help your heart

While previous research has suggested a link between low levels of vitamin D in the blood and an increased risk of cardiovascular disease, a new Michigan State University...

Human-on-a-chip model tests cancer drug efficacy a…

A reconfigurable "body-on-a-chip" model could transform drug development by simultaneously measuring compound efficacy and toxicity, for both target cells and other organ...

Pathogen engineered to self-destruct underlies can…

A team of investigators has developed a cancer vaccine technology using live, attenuated pathogens as vectors. A feature of the vaccine causes these bacteria to self-dest...

Artificial DNA can control release of active ingre…

A drug with three active ingredients that are released in sequence at specific times: Thanks to the work of a team at the Technical University of Munich (TUM), what was o...

How gastric stem cells fight bacteria

Stem cells are not only key players in tissue regeneration, they are also capable of taking direct action against bacteria. This is the finding of a study conducted by re...

Researchers identify enzyme that suppresses immune…

Immunotherapies have transformed cancer care, but their successes have been limited for reasons that are both complex and perplexing. In breast cancer especially, only a ...